| HOME >> BIOLOGY >> TECHNOLOGY |
SAN FRANCISCO, Feb. 14, 2011 /PRNewswire/ -- SARcode Corporation has named Todd Creech as Chief Financial Officer and Vice President of Business Development effective February 1, 2011. Creech has been fulfilling both positions as a consultant to SARcode since November 2010.
(Photo: http://photos.prnewswire.com/prnh/20110214/FL47222LOGO )
"Todd comes to SARcode with a wealth of experience in finance and leadership roles and has demonstrated great success in helping to drive positive results within this industry. He will be a tremendous asset to SARcode as we continue to develop our lead compound, SAR 1118," said Quinton Oswald, Chief Executive Officer of SARcode Corporation. "His knowledge of ophthalmology and emerging biopharmaceutical companies will be extremely beneficial as we move forward. We are very excited to have Todd join our team."
Creech has over 11 years of executive experience in finance and business development in the pharmaceutical and biotech industries, predominantly with early-stage companies. Most recently, he served as Chief Financial Officer at Sirion Therapeutics, where he was responsible for financing strategy, accounting, capital structure, treasury, legal, and information technology. Sirion raised over $100 million in debt and equity to support the license and development of six clinical programs, two of which were approved by the FDA and commercialized. In the first half of 2010, Todd led the sale of Sirion's assets to Alcon and Bausch and Lomb.
Prior to his tenure at Sirion, Creech worked with NovaQuest, the investment group within Quintiles, Inc., structuring, placing and managing capital investments into emerging biotech and specialty pharmaceutical companies. Additionally, his past experience includes co-founding Centice, an optical sensor spin-out of Duke University, and over 10 years of consulting experien
'/>"/>
| SOURCE SARcode Corporation Copyright©2010 PR Newswire. All rights reserved |